Biological, Biochemical, and Molecular Characterization of a New Clinical Trichophyton rubrum Isolate Resistant to Terbinafine

ABSTRACT We have characterized a new clinical strain of Trichophyton rubrum highly resistant to terbinafine but exhibiting normal susceptibility to drugs with other mechanisms of action. Resistance to terbinafine in this strain is caused by a missense mutation in the squalene epoxidase gene leading to the amino acid substitution F397L.

[1]  C. Osborne,et al.  Amino Acid Substitution in Trichophyton rubrum Squalene Epoxidase Associated with Resistance to Terbinafine , 2005, Antimicrobial Agents and Chemotherapy.

[2]  M. Ghannoum,et al.  Biochemical characterization of terbinafine-resistant Trichophyton rubrum isolates. , 2004, Medical mycology.

[3]  G. Goldman,et al.  In Vitro Evolution of Itraconazole Resistance in Aspergillus fumigatus Involves Multiple Mechanisms of Resistance , 2004, Antimicrobial Agents and Chemotherapy.

[4]  Aditya K. Gupta,et al.  Evaluation of in vitro Resistance in Patients with Onychomycosis Who Fail Antifungal Therapy , 2004, Dermatology.

[5]  K. Landl,et al.  Molecular Mechanism of Terbinafine Resistance in Saccharomyces cerevisiae , 2003, Antimicrobial Agents and Chemotherapy.

[6]  C. Osborne,et al.  In Vitro Analysis of the Ability of Trichophyton rubrum To Become Resistant to Terbinafine , 2003, Antimicrobial Agents and Chemotherapy.

[7]  Aditya K. Gupta,et al.  In vitro susceptibility testing of ciclopirox, terbinafine, ketoconazole and itraconazole against dermatophytes and nondermatophytes, and in vitro evaluation of combination antifungal activity , 2003, The British journal of dermatology.

[8]  Rodrigo Lopez,et al.  Multiple sequence alignment with the Clustal series of programs , 2003, Nucleic Acids Res..

[9]  D. Stevens,et al.  Antifungal drug resistance. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  M. Ghannoum,et al.  Clinical Trichophyton rubrum Strain Exhibiting Primary Resistance to Terbinafine , 2003, Antimicrobial Agents and Chemotherapy.

[11]  D. Sanglard.  Clinical relevance of mechanisms of antifungal drug resistance in yeasts. , 2002, Enfermedades infecciosas y microbiologia clinica.

[12]  Dominique Sanglard,et al.  Resistance of human fungal pathogens to antifungal drugs. , 2002, Current opinion in microbiology.

[13]  N. Ryder,et al.  In vitro susceptibility of Microsporum canis and other dermatophyte isolates from veterinary infections during therapy with terbinafine or griseofulvin. , 2002, Medical mycology.

[14]  M. Rinaldi,et al.  Comparison of In Vitro Activities of Voriconazole and Five Established Antifungal Agents against Different Species of Dermatophytes Using a Broth Macrodilution Method , 2001, Journal of Clinical Microbiology.

[15]  J. Guarro,et al.  In vitro Susceptibility to Itraconazole, Clotrimazole, Ketoconazole and Terbinafine of 100 Isolates of Trichophyton rubrum , 2000, Chemotherapy.

[16]  B. Elewski,et al.  Antifungal susceptibilities and genetic relatedness of serial Trichophyton rubrum isolates from patients with onychomycosis of the toenail. , 1999, Mycoses.

[17]  N. Ryder,et al.  Differential inhibition of fungal amd mammalian squalene epoxidases by the benzylamine SDZ SBA 586 in comparison with the allylamine terbinafine. , 1997, Archives of biochemistry and biophysics.

[18]  N. Ryder,et al.  Cloning and expression of squalene epoxidase from the pathogenic yeast Candida albicans. , 1997, Gene.

[19]  N. Ryder,et al.  Characterization of squalene epoxidase activity from the dermatophyte Trichophyton rubrum and its inhibition by terbinafine and other antimycotic agents , 1996, Antimicrobial agents and chemotherapy.

[20]  E. Bruck,et al.  National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.